All articles tagged with #masimo
Originally Published 4 months ago — by The Verge
Medical tech company Masimo is suing US Customs and Border Protection to challenge the decision allowing Apple to restore blood oxygen tracking on Apple Watches, claiming the agency failed to notify Masimo of the reversal of import restrictions and alleging patent infringement by Apple.
Originally Published 4 months ago — by 9to5Mac
Masimo has filed a lawsuit against US Customs and Border Protection, alleging they overstepped their authority by reversing a decision that allowed Apple to reintroduce the Blood Oxygen feature on the Apple Watch, which Masimo claims infringes on its patents. The company seeks a court order to reinstate the original ruling and prevent the feature's reintroduction via software updates.
Originally Published 4 months ago — by Bloomberg Law News
Masimo has sued US Customs and Border Protection, claiming it unlawfully reversed a decision that allowed Apple to restore a blood-oxygen monitoring feature on Apple Watches, which Masimo alleges infringes its patents. The company seeks to block the enforcement of CBP's recent ruling and restore the original decision that restricted imports of Apple Watches with the feature enabled, arguing the reversal was unlawful and violated procedural policies.
Originally Published 5 months ago — by Gizmodo
Apple Watch models in the U.S. will regain blood oxygen tracking via a software update following a patent dispute with Masimo, with the feature now measured on the iPhone and available on Series 9, Series 10, and Ultra 2 models, just ahead of new product launches.
Originally Published 6 months ago — by 9to5Mac
Apple is appealing a U.S. court ruling that banned the sale of certain Apple Watch models with blood-oxygen sensors due to patent infringement claims by Masimo, arguing that the ban unjustly deprives users of a feature and questioning the basis of the patent dispute related to prototypes versus finished products.
Originally Published 6 months ago — by Engadget
Apple is appealing a trade ban that forced it to remove the blood oxygen sensor from its Apple Watch due to patent disputes with Masimo, with ongoing legal battles over the sensor's legality and potential reintroduction in future models.
Originally Published 1 year ago — by MacRumors
Apple and Masimo are engaged in a legal battle over alleged trade secret theft and patent infringement related to the Apple Watch's blood oxygen sensing feature. Masimo accuses Apple of poaching employees and stealing technology, seeking an injunction rather than monetary damages. Despite an ITC ruling against Apple, which led to disabling the feature in U.S. sales, Apple continues to appeal. Masimo's legal efforts have yet to significantly impact Apple's business.
Originally Published 1 year ago — by 9to5Mac
The Apple Watch Series 9 and Ultra 2 are facing an ITC situation due to patent infringement, resulting in a ban on their sale in the United States. Apple is still selling the devices with the blood oxygen features disabled, and third-party retailers continue to offer them with the features intact. The ITC's decision has led to a series of legal maneuvers and appeals from Apple, including a redesign and a software update to address the issue. The situation remains ongoing, with the US appeals court temporarily halting the ban, while the Biden administration upholds the ITC's ruling.
Originally Published 1 year ago — by The Verge
Apple has filed a 916-page appeal to the Federal Circuit over the ban on sales of Apple Watch Series 9 and Ultra 2, which was imposed by the International Trade Commission due to patent infringement claims by medical device-maker Masimo. Apple's appeal argues that Masimo lacked an actual smartwatch and domestic industry at the time of the complaint, and questions the jurisdiction of the ITC. The appeal raises concerns about the potential implications of the decision and highlights the ongoing legal battles between tech companies and the ITC.
Originally Published 1 year ago — by CNBC
Activist investor Politan Capital, a 9% shareholder in health-tech company Masimo, is planning a second proxy fight to nominate two directors to the board following Masimo's announcement of a potential spinoff of its audio unit. The move comes after the activist's first proxy fight, which resulted in two board seats. Politan's nominees are former Agilent executive Darlene Solomon and former Stryker CFO Bill Jellison, and if successful, the investor would control four of the company's six board seats. Masimo's CEO, Joe Kiani, has been accused of rebuffing the activist's efforts and refusing to provide basic information, leading to the intensification of the proxy fight.
Originally Published 1 year ago — by 9to5Mac
Jailbreaking an iPhone can re-enable blood oxygen measurement on an Apple Watch, revealing the ongoing court battle between Apple and health tech company Masimo. The feature was initially disabled despite the Apple Watch's capability to measure blood oxygen. Masimo accused Apple of stealing its technology, leading to a lawsuit and import ban on certain Apple Watch models. Despite the ban, Masimo demonstrated that the feature could be re-enabled using a jailbroken iPhone, but ultimately lost the argument. Apple has appealed the ruling, and even if it loses, it can re-enable the feature through a software update by August 2028 when Masimo's patent expires.
Originally Published 1 year ago — by MacRumors
Apple has been selling Apple Watch Series 9 and Ultra 2 without the blood oxygen monitoring feature in the U.S. due to patent infringement issues with Masimo. However, new information from the U.S. Customs and Border Protection confirms that reactivating pulse oximetry through a software update is possible, and the patents in question will expire in 2028. Apple has filed an appeal to overturn the ruling, and there is also the option to settle with Masimo. Meanwhile, the disabled feature only applies to U.S. models, and the watches remain fully functional in other countries.
Originally Published 1 year ago — by PhoneArena
Apple's latest Apple Watch Series 9 and Apple Watch Ultra 2 do not include a working pulse oximeter due to a patent infringement ruling against Apple by Masimo. Despite the option to license the patent, Apple's CEO Tim Cook has stated that the company has no intention to pay for it and is focused on winning an appeal. The absence of the pulse oximeter feature could prompt Apple to develop a non-invasive blood glucose monitor, but this strategy carries the risk of facing higher licensing costs if the appeal is unsuccessful.
Originally Published 1 year ago — by 9to5Mac
Apple CEO Tim Cook stated that the company is focused on appealing the Apple Watch ban and not interested in settling with Masimo over the contested blood oxygen feature, despite the ongoing patent battle. The Apple Watch Series 9 and Ultra 2 are still being sold in the US with the blood oxygen feature disabled, and Cook emphasized that there are other reasons to buy the watch. Masimo CEO Joe Kiani has expressed openness to a settlement, but Apple has not engaged in serious discussions. Despite the ban, the watches can still be purchased from third-party retailers with the blood oxygen app and features intact.
Originally Published 1 year ago — by AppleInsider
Apple CEO Tim Cook implies that the company has no intention to license Masimo's blood oxygen detection technology to end the import ban on Apple Watches, opting to focus on appeals instead. The import ban affects Apple Watches with a blood oxygen sensor, prompting Apple to disable the sensor in newer models to continue sales. Masimo has expressed willingness to settle with Apple, but the tech giant has shown no intention to initiate negotiations.